Stay updated on Intratumoral SD-101 + Pembrolizumab Clinical Trial
Sign up to get notified when there's something new on the Intratumoral SD-101 + Pembrolizumab Clinical Trial page.

Latest updates to the Intratumoral SD-101 + Pembrolizumab Clinical Trial page
- ChecktodayNo Change Detected
- Check7 days agoNo Change Detected
- Check15 days agoChange DetectedThe site shows an updated revision from v3.5.2 to v3.5.3, indicating an incremental platform release. This update does not modify the study details presented on the page.SummaryDifference0.0%

- Check22 days agoChange DetectedThe page now shows a different site revision number (v3.5.2 instead of v3.5.0). No other content on the study record appears to be changed.SummaryDifference0.0%

- Check44 days agoChange DetectedAdded 'Squamous cell carcinoma of the head and neck' as a disease topic and introduced a Resources section with the Genetic and Rare Diseases Information Center.SummaryDifference0.1%

- Check51 days agoChange DetectedRevision label updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check58 days agoChange DetectedLayout and navigation appear adjusted between the two screenshots, while core study sections such as endpoints, eligibility criteria, and enrollment show no visible changes.SummaryDifference0.0%

- Check65 days agoChange DetectedFooter revision updated from v3.4.2 to v3.4.3. No other visible changes to content or layout on the Study Details page.SummaryDifference0.1%

Stay in the know with updates to Intratumoral SD-101 + Pembrolizumab Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Intratumoral SD-101 + Pembrolizumab Clinical Trial page.